India has long supplied affordable generic medicines across continents, earning global trust. However, Shri Nadda stressed that the country must now anchor global supply chains not only through scale but also through quality, reliability, and innovation.
Quality and Innovation at the Core
Highlighting India’s growing leadership in the pharmaceutical sector, the Minister underscored that quality must be embedded as a core organizational value rather than treated as a compliance requirement. He called upon industry stakeholders to strengthen quality systems, human resources, and infrastructure.
According to him, India’s transformation into a global pharma innovation hub will depend on sustained investment in research and development, advanced manufacturing technologies, and regulatory excellence. “Growth must be balanced with responsibility and trust,” he noted.
Biopharma Shakti to Boost Manufacturing
Referring to major government initiatives, Shri Nadda pointed to the ₹10,000 crore Biopharma Shakti initiative, which aims to position India as a global biopharmaceutical manufacturing hub. The scheme is expected to strengthen domestic production capacity while expanding research capabilities.
The initiative seeks to reduce dependence on imports for critical components and foster cutting-edge biopharmaceutical research. By strengthening indigenous capacity, India hopes to enhance healthcare security and global competitiveness.
PRIP Scheme Driving Research and MedTech Growth
The Minister also highlighted the Promotion of Research and Innovation in Pharma MedTech (PRIP) scheme, designed to accelerate innovation in new medicines, complex generics, vaccines, and advanced medical technologies.
The PRIP scheme is expected to bridge gaps between academia, startups, and established pharmaceutical firms. By encouraging collaboration and innovation, the government aims to move India up the pharmaceutical value chain.
Responsible Use of Artificial Intelligence
Emerging technologies, especially artificial intelligence, will play a transformative role in India’s pharmaceutical evolution, Shri Nadda said. Responsible deployment of AI can significantly enhance predictive diagnostics, pharmaceutical traceability, pharmacovigilance, and quality management systems.
AI-powered solutions are already helping streamline supply chains and improve monitoring of drug safety. The Minister stressed that technology adoption must be ethical, transparent, and patient-centric.
Balancing Scale with Trust
Reiterating India’s long-term vision, Shri Nadda said the country aims to combine scale with trust, innovation with collaboration, and growth with responsibility. The pharmaceutical sector, he noted, has a crucial role in strengthening global healthcare outcomes.
India currently supplies medicines to more than 200 countries and plays a vital role in global vaccine distribution. Moving forward, the country intends to deepen its presence not just as a supplier of affordable drugs but also as a pioneer in research-driven solutions.
